Please try another search
For the nine months ended 30 September 2019, OWCPharmaceutical Research Corp revenues was not reported. Netincome applicable to common stockholders totaled $3.8M vs.loss of $6.6M. Net income reflects Revaluation of embeddedderivative relat decrease of 98% to $49K (expense), OtherNon Operating I/E decrease from $823K (expense) to $0K,General and administrative decrease of 33% to $1.4M(expense).
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -0.59 | -0.71 | -0.78 | -1.68 |
Net Income | -0.29 | 7.71 | -1 | -5.08 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Assets | 1.77 | 2.33 | 2.95 | 3.55 |
Total Liabilities | 1.47 | 1.75 | 10.25 | 10.77 |
Total Equity | 0.31 | 0.58 | -7.3 | -7.21 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -1.99 | -1.62 | -0.67 | -2.5 |
Cash From Investing Activities | -0 | -0 | 0 | -0.03 |
Cash From Financing Activities | 0 | 0 | 0 | 5.02 |
Net Change in Cash | -2 | -1.62 | -0.66 | 2.49 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review